NBIX — Neurocrine Biosciences, Inc.

Neurocrine Biosciences (NBIX) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Product Sales: Exceeded $2.8 billion, marking a 22% year-over-year growth.
• INGREZZA Revenue: Generated over $2.5 billion, up 9% year-over-year, driven by double-digit volume growth but impacted by pricing concessions for formulary access.
• CRENESSITY Revenue: Achieved over $300 million in net sales in its first full year, capturing approximately 10% of the addressable classic congenital adrenal hyperplasia (CAH) patient population.
• Cash Position: Increased to $2.5 billion from $1.8 billion at the end of 2024.
• Non-GAAP Operating Margin: Approximately 30% for 2025, translating to about $850 million in operating income.

2. Strategic Updates and Business Highlights

• INGREZZA: Continued strong performance with record new prescriptions, supported by an expanded sales force. The company expects double-digit volume-driven growth in 2026, with sales projected between $2.7 billion and $2.8 billion.
• CRENESSITY: Strong launch performance with a favorable safety profile and rapid adoption among prescribers. The company aims to establish it as a second blockbuster product.
• Pipeline Development: Focus on advancing next-generation VMAT2 inhibitors and CRF-based therapies. Two Phase III programs are ongoing, with data expected in 2027.
• Sales Force Expansion: Plans to enhance the CRENESSITY sales team to deepen engagement with existing prescribers and reach new potential prescribers outside endocrinology.

3. Forward Guidance and Outlook

• 2026 Guidance for INGREZZA: Expected sales growth of approximately 10%, with stable net pricing anticipated.
• CRENESSITY: No specific sales guidance provided for 2026 due to the ongoing learning phase of the launch, but the company is optimistic about continued growth.
• R&D Investments: Increased R&D expenses expected in 2026, primarily driven by Phase III trials and new program initiations.

4. Bad News, Challenges, or Points of Concern

• Pricing Pressure: INGREZZA faces ongoing pricing pressures due to formulary access strategies, with a projected negative 4% price impact in 2026.
• Market Penetration: While CRENESSITY has made significant strides, only about 10% of the CAH population is currently being treated, indicating substantial room for growth but also highlighting the challenges in reaching broader patient bases.
• Seasonality and Patient Dynamics: Uncertainty regarding potential seasonality in patient demand for CRENESSITY, with the company still gathering data to understand patient enrollment trends.

5. Notable Q&A Insights

• Market Dynamics: Executives noted that many prescribers are still learning about CRENESSITY, with a significant portion having only treated one patient. Education and outreach efforts are crucial for expanding adoption.
• Competitor Landscape: Concerns about future competitors, such as ACTH antagonists, were addressed, with management confident in CRENESSITY's differentiated profile and established market presence.
• Sales Force Impact: The expansion of the sales force is seen as essential for maintaining patient flow and increasing penetration in the CAH market.
• Patient Management: The company is leveraging AI and data analytics to identify potential prescribers and enhance patient engagement strategies.

Overall, Neurocrine Biosciences is positioned for continued growth in 2026, driven by strong product performance and strategic investments, although challenges related to pricing and market penetration remain.